阿巴塔克普
医学
CD80
CD86
类风湿性关节炎
免疫学
T细胞
共刺激
关节炎
癌症研究
CD28
免疫系统
抗体
生物
CD40
细胞毒性T细胞
体外
生物化学
美罗华
作者
Michael Bonelli,Clemens Scheinecker
出处
期刊:Current Opinion in Rheumatology
[Ovid Technologies (Wolters Kluwer)]
日期:2018-05-01
卷期号:30 (3): 295-300
被引量:41
标识
DOI:10.1097/bor.0000000000000491
摘要
Purpose of review The purpose of this review is to summarize the current knowledge concerning the mechanisms of action of Abatacept in patients with rheumatoid arthritis. Recent findings Abatacept (CTLA-4Ig) represents a soluble, recombinant, fully humanized fusion protein, comprising the extracellular domain of CTLA-4 and the Fc portion of IgG1. Abatacept binds to the costimulatory molecules CD80 and CD86 on antigen-presenting cells (APC), thereby blocking interaction with CD28 on T cells. In humans, Abatacept treatment was shown to be effective in patients with various autoinflammatory diseases including rheumatoid arthritis. Although the prevention of T-cell activation by interfering with signaling via CD28 still represents the main mechanism of action Abatacept acts on additional cell populations including regulatory T cells (Treg), monocytes/macrophages, osteoclasts, and B cells. Summary Effects of Abatacept on other cell populations besides T cells have to be taken into account and might represent a valuable contribution to the therapeutic success.
科研通智能强力驱动
Strongly Powered by AbleSci AI